Lymphoma Clinical Trials in Baltimore

Showing 321-340 of 343 trials

Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

NCT00081068

RATIONALE: Monoclonal antibodies, such as alemtuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: This phase II trial is studying how well alemtuzumab works in treating patients with Waldenstrom's macroglobulinemia.

Lymphoma

Jonsson Comprehensive Cancer CenterStarted Jan 2004

Los Angeles, California, United States • Denver, Colorado, United States • Chicago, Illinois, United States +12 more locations

COMPLETEDPHASE3< 1 mile

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

NCT00003805

RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count. It is not yet known which regimen of antibiotics is most effective in preventing infection in these patients. PURPOSE: Randomized phase III trial to study the effectiveness of piperacillin-tazobactam with or without vancomycin in reducing fever in patients who have leukemia, lymphoma, or Hodgkin's disease.

Bone Marrow SuppressionFever, Sweats, and Hot FlashesInfection+6 more

European Organisation for Research and Treatment of Cancer - EORTC859 participantsStarted Nov 1997

Baltimore, Maryland, United States • Boston, Massachusetts, United States • Antwerp, Belgium +25 more locations

Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

Lymphoma Trials in Other Cities

UCN-01 in Treating Patients With Advanced Cancer

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma

A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma

A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

Phase I Study of Intrathecal Topotecan

Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Other Conditions in Baltimore